중독 장애 약물 시장 : 제형, 약제 클래스별, 제품 유형, 투여 경로, 유통 채널, 최종 사용자별 - 세계 시장 예측(2026-2032년)

The Addiction Disorders Drugs Market is projected to grow by USD 39.33 billion at a CAGR of 9.85% by 2032.

The addiction disorders drugs market sits at the intersection of urgent public health need, medication-assisted treatment expansion, and fast-changing policy. Demand is driven by opioid use disorder, alcohol use disorder, tobacco dependence, stimulant use disorder, and polysubstance use, with treatment strategies spanning agonists, partial agonists, antagonists, aversive agents, withdrawal management drugs, and relapse-prevention therapies.

Commercial opportunity is strongest where evidence-based pharmacotherapy is integrated with behavioral health, primary care, telehealth, and long-term recovery support. Market leaders are increasingly focused on long-acting injectable formulations, digital adherence support, expanded access models, overdose reversal medicines, and combination care pathways that improve retention, reduce relapse, and address comorbid mental health conditions.

Transformative Shifts in Addiction Treatment

The market is being reshaped by a shift from acute detoxification to chronic disease management. Addiction is increasingly treated as a relapsing medical condition requiring sustained pharmacotherapy, coordinated behavioral care, and measurable outcomes. This shift supports broader use of buprenorphine, methadone, naltrexone, acamprosate, disulfiram, nicotine replacement therapies, varenicline, cytisine where approved, and emerging candidates for stimulant and cannabis use disorders.

Regulatory and reimbursement changes are also changing access. In the U.S., the removal of the federal X-waiver requirement for buprenorphine prescribing expanded the eligible prescriber base, while many countries are revising harm-reduction, opioid agonist therapy, and take-home medication policies. At the same time, payers and public health systems are scrutinizing real-world evidence, adherence, diversion controls, safety monitoring, and total cost-of-care benefits.

Innovation is moving beyond conventional oral therapies. Long-acting injectables and implants support adherence and reduce daily dosing burden, while intranasal overdose reversal products have increased community-based emergency response capacity. The next competitive phase will favor organizations able to prove clinical durability, safety in complex populations, compatibility with behavioral health services, and interoperability with digital and community care models.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is beginning to create cumulative value across discovery, development, access, and patient support for addiction disorder medications. In drug discovery, AI-enabled target identification, molecular screening, and biomarker analysis can help prioritize candidates for conditions with limited approved pharmacologic options, including stimulant use disorder. In clinical development, machine learning can support trial design by identifying risk profiles, predicting dropout, strengthening site selection, and improving protocol feasibility.

AI is also influencing care delivery. Predictive analytics can flag relapse risk, overdose vulnerability, treatment discontinuation, and medication nonadherence when used with validated clinical data and appropriate privacy safeguards. Natural language processing may help health systems identify substance use patterns in clinical notes, while AI-supported digital therapeutics can reinforce behavioral interventions between visits and support care coordination across primary care, psychiatry, and community programs.

The cumulative impact will depend on governance. Algorithms used in addiction care must be clinically validated, bias-tested, explainable, and transparent because substance use disorders are closely linked to stigma, criminal justice exposure, unstable housing, and other social determinants of health. Organizations that combine AI with rigorous evidence generation, patient consent, cybersecurity, and regulatory-grade data practices will be better positioned to earn provider, payer, and patient trust.

Key Regional Insights

North America remains a central market for addiction disorders drugs because of high treatment demand, established medication-assisted treatment infrastructure, and significant public funding for opioid response. The United States has the deepest commercial ecosystem for buprenorphine, naltrexone, methadone services, naloxone, alcohol use disorder medications, and smoking cessation therapies, while Canada continues to expand supervised consumption, opioid agonist therapy, and safer supply discussions in response to toxic drug supply risks.

Europe shows strong policy support for harm reduction and opioid substitution treatment, particularly in Western and Northern European health systems. European public health frameworks support surveillance, prevention, and access to evidence-based treatment, although reimbursement and prescribing rules vary by country. Asia-Pacific presents a mixed but expanding opportunity, with Japan, Australia, South Korea, China, India, and ASEAN markets showing different levels of treatment availability, stigma reduction, tobacco control policy, mental health investment, and regulatory openness.

Latin America is gaining relevance as governments address alcohol dependence, tobacco use, and illicit drug-related harms, with Brazil and Mexico acting as important demand centers. The Middle East and Africa remain underpenetrated for addiction pharmacotherapy due to stigma, specialist shortages, limited reimbursement, and uneven harm-reduction infrastructure, but GCC countries are investing in specialized behavioral health services, and parts of Africa face rising need for accessible, low-cost treatment and overdose prevention support.

Key Group Insights

Within ASEAN, addiction disorder drug demand is shaped by large populations, variable regulatory approaches, and rising focus on mental health system capacity. Access remains uneven across member states, but urban hospital networks, tobacco control programs, and public health initiatives are creating pathways for pharmacotherapy adoption, particularly for alcohol, tobacco, and opioid-related conditions where policy permits evidence-based treatment.

The GCC is increasingly relevant as governments invest in modern healthcare infrastructure, specialized psychiatric care, and national addiction treatment initiatives. Cultural stigma remains a barrier, but centralized healthcare planning can accelerate adoption of evidence-based therapies when supported by reimbursement, clinician training, confidential care pathways, and integration with broader mental health reforms. The European Union offers one of the most structured policy environments, with coordinated surveillance and harm-reduction guidance supporting long-term treatment models and cross-country evidence sharing.

BRICS countries represent high-volume opportunity, led by China, India, and Brazil, but access depends on affordability, domestic manufacturing, public-sector procurement, and regulatory alignment with evidence-based treatment standards. G7 markets provide the strongest environment for premium formulations, long-acting injectables, evidence generation, overdose reversal access, and digital care integration. NATO countries overlap significantly with North American and European markets where defense, veteran, and public health systems increasingly recognize substance use disorders as workforce, family, and community health priorities.

Key Country Insights

The United States is the most influential country market due to high opioid-related morbidity, broad medication-assisted treatment use, and active regulatory pathways for overdose reversal and relapse-prevention products. Canada is expanding harm-reduction-linked treatment capacity and opioid agonist therapy access, while Mexico and Brazil represent important Latin American markets where public-sector access, tobacco control, and alcohol-related disease burden shape demand for addiction pharmacotherapy.

In Europe, the United Kingdom, Germany, France, Italy, and Spain support mature treatment systems with varying degrees of opioid substitution therapy, alcohol use disorder medication use, and smoking cessation reimbursement. Russia has a distinct treatment environment because opioid agonist therapy is restricted, affecting market access for standard opioid use disorder medications. Germany and France are especially important for evidence-based prescribing, reimbursement evaluation, specialist care networks, and structured addiction medicine services.

China and India offer large long-term potential because of population scale, tobacco burden, alcohol-related harms, and growing investment in mental health services, but adoption depends on regulation, stigma reduction, affordability, and physician training. Japan, Australia, and South Korea offer more advanced regulatory and reimbursement environments for selected therapies, with Australia notable for harm-reduction experience and opioid pharmacotherapy access, while Japan and South Korea offer opportunities in smoking cessation, alcohol treatment, and carefully regulated addiction medicine.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize therapies that improve retention and reduce relapse, because adherence remains one of the most important barriers in addiction treatment. Long-acting injectables, depot formulations, abuse-deterrent delivery, overdose reversal products, and patient-centered dosing models should be supported with real-world evidence demonstrating fewer emergency visits, lower overdose risk, improved medication persistence, and stronger continuity of care.

Organizations should also build market access strategies around integrated care. Partnerships with primary care groups, community clinics, telehealth providers, behavioral health networks, pharmacies, harm-reduction programs, and correctional health systems can expand reach to populations that often remain outside traditional specialty treatment. Education for prescribers is essential, especially in markets where stigma and limited addiction medicine training constrain uptake.

Finally, leaders should invest in ethical AI, pharmacovigilance, and health equity. Evidence packages should include diverse populations, comorbid psychiatric conditions, pregnancy considerations where applicable, and social risk factors. Stakeholders that demonstrate safety, measurable outcomes, affordability, privacy protection, and responsible data use will be best positioned for payer acceptance and long-term public health relevance.

Research Methodology

This executive summary is based on secondary research from authoritative public health, regulatory, and scientific sources, including the World Health Organization, UN Office on Drugs and Crime, U.S. Centers for Disease Control and Prevention, U.S. Food and Drug Administration, European drug monitoring authorities, national health agencies, peer-reviewed medical literature, and published clinical guidelines.

The methodology emphasizes triangulation of epidemiology, treatment guidelines, regulatory developments, approved medication classes, policy reforms, harm-reduction practices, and regional access dynamics. Market interpretation focuses on verified disease burden, evidence-based pharmacotherapy adoption, reimbursement conditions, regulatory access, and innovation trends rather than unsupported projections.

Insights were synthesized through an industry lens, aligning clinical facts with commercial implications across regions, groups, and country markets. The analysis prioritizes data-backed statements, current treatment standards, observable policy shifts, and practical implications relevant to addiction disorders drugs.

Conclusion

The addiction disorders drugs market is evolving from fragmented treatment access toward integrated, evidence-based, and outcomes-driven care. Rising global burden, sustained overdose risk, alcohol-related harm, stimulant use concerns, and tobacco dependence continue to support demand for pharmacologic interventions that improve retention, prevent relapse, reduce withdrawal burden, and lower mortality.

Future progress will be shaped by long-acting formulations, expanded prescribing capacity, harm-reduction integration, overdose reversal access, AI-enabled patient support, and stronger real-world evidence. Organizations that combine clinical efficacy with affordability, privacy protection, equitable access, and partnerships across behavioral health ecosystems will be best positioned to lead in this high-need therapeutic area.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Addiction Disorders Drugs Market, by Dosage Form

• 7.1. Capsule
• 7.2. Film
• 7.3. Injectable Solution
• 7.4. Patch
• 7.5. Tablet

8. Addiction Disorders Drugs Market, by Drug Class

• 8.1. Alcohol
  • 8.1.1. Acamprosate
  • 8.1.2. Disulfiram
  • 8.1.3. Naltrexone
• 8.2. Nicotine
• 8.3. Opioid
  • 8.3.1. Buprenorphine
  • 8.3.2. Methadone
  • 8.3.3. Naltrexone

9. Addiction Disorders Drugs Market, by Product Type

• 9.1. Branded
• 9.2. Generic

10. Addiction Disorders Drugs Market, by Administration Route

• 10.1. Injectable
• 10.2. Oral
• 10.3. Sublingual
• 10.4. Transdermal

11. Addiction Disorders Drugs Market, by Distribution Channel

• 11.1. Hospital Pharmacy
• 11.2. Online Pharmacy
• 11.3. Retail Pharmacy

12. Addiction Disorders Drugs Market, by End User

• 12.1. Clinics
• 12.2. Homecare Settings
• 12.3. Hospitals

13. Addiction Disorders Drugs Market, by Region

• 13.1. Asia-Pacific
• 13.2. North America
• 13.3. Latin America
• 13.4. Europe
• 13.5. Middle East
• 13.6. Africa

14. Addiction Disorders Drugs Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Addiction Disorders Drugs Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Concentration Analysis, 2025
  • 16.1.1. Concentration Ratio (CR)
  • 16.1.2. Herfindahl Hirschman Index (HHI)
• 16.2. Recent Developments & Impact Analysis, 2025
• 16.3. Product Portfolio Analysis, 2025
• 16.4. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. Accord Healthcare Limited
• 17.2. Alkermes plc
• 17.3. Amneal Pharmaceuticals Inc.
• 17.4. Aurobindo Pharma Limited
• 17.5. Bausch Health Companies Inc
• 17.6. BioCorRx Inc.
• 17.7. BioDelivery Sciences International Inc
• 17.8. Braeburn Inc.
• 17.9. Camurus AB
• 17.10. Cipla Limited
• 17.11. Dr. Reddy's Laboratories Ltd
• 17.12. Eli Lilly and Company
• 17.13. Elite Pharmaceuticals Inc.
• 17.14. GlaxoSmithKline PLC
• 17.15. Glenmark Pharmaceuticals
• 17.16. H. Lundbeck A/S
• 17.17. Hikma Pharmaceuticals PLC
• 17.18. Indivior PLC
• 17.19. Insys Therapeutics Inc
• 17.20. Johnson & Johnson
• 17.21. Mallinckrodt Pharmaceuticals PLC
• 17.22. Novartis AG
• 17.23. Orexo AB
• 17.24. Pear Therapeutics
• 17.25. Pfizer Inc
• 17.26. Purdue Pharma L.P.
• 17.27. Reckitt Benckiser Pharmaceuticals Inc
• 17.28. Sun Pharmaceutical Industries Ltd
• 17.29. Teva Pharmaceutical Industries Ltd
• 17.30. Titan Pharmaceuticals Inc
• 17.31. Viatris Inc